BNGO BIONANO GENOMICS INC

Bionano to Participate in the H.C. Wainwright @ Home Event

Bionano to Participate in the H.C. Wainwright @ Home Event

SAN DIEGO, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will participate in the H.C. Wainwright @ Home Event on Wednesday, October 15th, 2025.

Conference & Webcast Details

Date:October 15, 2025
Time:10:00 a.m. to 11:00 a.m. ET
Presenter:Erik Holmlin, PhD, CEO of Bionano
Webcast:
  

A replay / recording of the session will be available following the conference through the Bionano website at  for at least 90 days.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit  or .

Bionano’s products are for research use only and not for use in diagnostic procedures.

Contacts

Company Contact:

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

Investor Relations:

Kelly Gura

Gilmartin Group

+1 (212) 229-6163



EN
07/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIONANO GENOMICS INC

 PRESS RELEASE

Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 202...

Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025 SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted how optical genome mapping (OGM) can enhance the detection of structural variants (SVs) with greater clarity and sensitivity than traditional cytogenetic and molecular techniques. Through platform presentations and poster sessions, multiple researchers emphasized the expanding u...

 PRESS RELEASE

Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payme...

Final 2026 Clinical Lab Fee Schedule Indicates a 47% Increase in Payment Determination for the Category I CPT Code for OGM use in Hematologic Malignancies SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026 posted by Centers for Medicare & Medicaid Services (CMS) indicates an increase of 47%, from $1263.53 to $1853.22, for the payment for the Cate...

 PRESS RELEASE

Bionano Reports Third Quarter 2025 Results and Highlights Recent Busin...

Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress Conference call today, November 13, 2025, at 4:30 PM ET SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. “Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We believe our performance in the third quarter and year-to-date validates this strategic shift and demon...

 PRESS RELEASE

Bionano Announces Publication Showing OGM Can Overcome Key Limitations...

Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study in Cancers from The University of Texas MD Anderson Cancer Center showing how optical genome mapping (OGM) can address key limitations of targeted RNA-sequencing (RNA-seq) panels in detecting therapeutically-relevant gene rearrangements in acute leukemias. This peer-reviewed publication, entitled “Comparative Analysis of Targete...

 PRESS RELEASE

Bionano to Report Third Quarter 2025 Financial Results and Host a Conf...

Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025 SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Thursday, November 13, 2025, at 4:30 p.m. Eastern Time to report financial results for the third quarter 2025 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Thursday, November 13th, 2025Time:4:30 p.m. ETParticipant Link:Webcast Link: Participants may access a live webcast of the call on the ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch